Expression and Significance of PD-1, PD-L1 and PD-L2 in T Cell Subsets and Myeloma Cells in Newly Diagnosed Multiple Myeloma Patients
10.3971/j.issn.1000-8578.2022.21.0352
- VernacularTitle:初诊多发性骨髓瘤患者T细胞亚群和骨髓瘤细胞中PD-1、PD-L1及PD-L2的表达与意义
- Author:
Yinjuan MA
1
;
Ke YANG
;
Xiaying YANG
;
Jiaofeng BAI
;
Hai BAI
;
Tao WU
;
Lihua FU
;
Junfeng JIANG
;
Yaozhu PAN
Author Information
1. Department of Hematology, The 940th Hospital of Joint Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
- Publication Type:Research Article
- Keywords:
Multiple myeloma;
Programmed death receptor-1;
Programmed death ligand-1;
Programmed death ligand-2
- From:
Cancer Research on Prevention and Treatment
2022;49(1):40-45
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma (NDMM) patients and their relation with clinical features. Methods We collected the bone marrow and clinical data of 22 NDMM patients and 18 cases of healthy controls. We sorted CD4+T cells, CD8+T cells and myeloma cells by flow cytometry, and observed the expression of PD-1 and PD-L1/2. Results Compared with the control group, the proportion of CD8+T cells in the NDMM group was significantly higher, while the ratio of CD4+/CD8+ was significantly lower (both P < 0.05). The expression levels of PD-1 and PD-L2 in CD4+T cells in the NDMM group were significantly higher than those in the control group (both P < 0.05). The expression levels of PD-1, PD-L1 and PD-L2 in T cell subsets and myeloma cells of NDMM patients were not correlated with the gender, age, immune typing, Durie-Salmon stage and subtypes, ISS stage or mSMART3.0 stratification (both P > 0.05). Conclusion Most of MM patients suffering immune abnormality, which may be associated with the mutual immunosuppressive effects between T lymphocytes and plasma cells which expressing PD-1 and PD-L1/2.
